Immune Therapeutics, Inc.
IMUN · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $462 | $106 |
| G&A Expenses | $0 | $0 | $690 | $233 |
| SG&A Expenses | $288 | $254,250 | $690 | $233 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $13 |
| Operating Expenses | $288 | $254,250 | $1,151 | $352 |
| Operating Income | $0 | $0 | $1,192 | -$352 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $117 | -$36 |
| Pre-Tax Income | $0 | $0 | $1,309 | -$389 |
| Tax Expense | $0 | $0 | -$14 | $0 |
| Net Income | $0 | $0 | $1,323 | -$389 |
| % Margin | – | – | – | – |
| EPS | 0 | 0 | 0.032 | -0.01 |
| % Growth | – | -100% | 418% | – |
| EPS Diluted | 0 | 0 | -66,150 | -0.01 |
| Weighted Avg Shares Out | 832 | 41,620 | 41,620 | 38,955 |
| Weighted Avg Shares Out Dil | 83,239 | 62,429 | 41,620 | 38,955 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$45 | $36 |
| Depreciation & Amortization | $0 | $0 | -$40 | $14 |
| EBITDA | $0 | $0 | $1,224 | -$411 |
| % Margin | – | – | – | – |